Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor

References

• Armani S, Ting L, Sauter N, et al. (2017). Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig 37:465–72.
   PubMed Web of Science ®Google Scholar
• Barbara JE, Kazmi F, Parkinson A, Buckley DB. (2013). Metabolism-dependent inhibition (MDI) of CYP3A4 by lapatinib: Evidence for formation of a metabolic intermediate (MI) complex with a nitroso/oxime metabolite formed via a nitrone intermediate. Drug Metab Dispos 41:1012–22.
   PubMed Web of Science ®Google Scholar
• Bernstein C, Bernstein H, Payne CM, Garewal H. (2002). DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 511:145–78.
   PubMed Web of Science ®Google Scholar
• Deeks ED. (2015). Olaparib: first global approval. Drugs 75:231–40.
   PubMed Web of Science ®Google Scholar
• de Murcia JM, Niedergang C, Trucco C, et al. (1997). Requirement of poly (ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U S A 94:7303–7.
   PubMed Web of Science ®Google Scholar
• Diaconu CH, Cuciureanu M, Vlase L, Cuciureanu R. (2011). Food-drug interactions: grapefruit juice. Rev Med Chir Soc Med Nat Iasi 115:245–50.
   PubMedGoogle Scholar
• Fontana E, Dansette PM, Poli SM. (2005). Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413–51.
   PubMed Web of Science ®Google Scholar
• Garimella T, Tao X, Sims K, et al. (2018). Effects of a fixed-dose co-formulation of daclatasvir, asunaprevir, and beclabuvir on the pharmacokinetics of a cocktail of cytochrome p450 and drug transporter substrates in healthy subjects. Drugs R D 18:55–65. doi: 10.1007/s40268-017-0222-8.
   PubMed Web of Science ®Google Scholar
• Giri P, Naidu S, Patel N, et al. (2017). Evaluation of in vitro cytochrome p450 inhibition and in vitro fate of structurally diverse n-oxide metabolites: Case studies with clozapine, levofloxacin, roflumilast, voriconazole and zopiclone. Eur J Drug Metab Pharmacokinet 42:677–88.
   PubMed Web of Science ®Google Scholar
• Giri P, Gupta L, Naidu S, et al. (2018). In vitro drug-drug interaction potential of sulfoxide and/or sulfone metabolites of albendazole, triclabendazole, aldicarb, methiocarb, montelukast and ziprasidone. Drug Metab Lett 12(2):101–16. doi: 10.2174/1872312812666180816164626. [Epub ahead of print]
   PubMedGoogle Scholar
• Hollenberg PF, Kent UM, Bumpus NN. (2008). Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chem Res Toxicol 21:189–205.
   PubMed Web of Science ®Google Scholar
• Jain MR, Mohapatra J, Bandhyopadhyay D, et al. (2018). Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1. Cancer Chemother Pharmacol 82:635–47.
   PubMed Web of Science ®Google Scholar
• Kopa P, Macieja A, Galita G, et al. (2018). DNA double strand breaks repair inhibitors: relevance as potential new anticancer therapeutics. Curr Med Chem. doi: 10.2174/0929867325666180214113154. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Lu Y, Liu Y, Pang Y, et al. (2018). Double-barreled gun: combination of PARP inhibitor with conventional chemotherapy. Pharmacol Ther 188:168–75. doi: 10.1016/j.pharmthera.2018.03.006. Epub 2018 Apr 3.
   PubMed Web of Science ®Google Scholar
• McCormick A, Swaisland H, Reddy VP, et al. (2018). In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly (ADP-ribose) polymerase inhibitor, on cytochrome P450. Xenobiotica 48:555–64.
   PubMed Web of Science ®Google Scholar
• Rescigno P, Chandler R, de Bono J. (2018). Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. Curr Opin Support Palliat Care 12:339–43. doi: 10.1097/SPC.0000000000000358.
   PubMed Web of Science ®Google Scholar
• Sabatucci I, Maltese G, Lepori S, et al. (2018). Rucaparib: a new treatment option for ovarian cancer. Expert Opin Pharmacother 19:765–71.
   PubMed Web of Science ®Google Scholar
• Schreiber V, Dantzer F, Ame JC, de Murcia G. (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517–28.
   PubMed Web of Science ®Google Scholar
• Schiewer MJ, Knudsen KE. (2014). Transcriptional roles of PARP1 in cancer. Mol Cancer Res 12:1069–80.
   PubMed Web of Science ®Google Scholar
• Scott LJ. (2017). Niraparib: first global approval. Drugs 77:1029–34.
   PubMed Web of Science ®Google Scholar
• Sisay M, Edessa D. (2017). PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecol Oncol Res Pract 4:18. doi: 10.1186/s40661-017-0055-8. eCollection 2017.
   PubMedGoogle Scholar
• Srinivas NR. (2013a). Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. J Pharm Pharm Sci 16:289–303.
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2013b). Is pomegranate juice a potential perpetrator of clinical drug-drug interactions? Review of the in vitro, preclinical and clinical evidence. Eur J Drug Metab Pharmacokinet 38:223–9.
   PubMed Web of Science ®Google Scholar
• Theile D, Hohmann N, Kiemel D, et al. (2017). Clementine juice has the potential for drug interactions – in vitro comparison with grapefruit and mandarin juice. Eur J Pharm Sci 97:247–56.
   PubMed Web of Science ®Google Scholar
• Williams D, Tao X, Zhu L, et al. (2017). Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator. Br J Clin Pharmacol 83:370–80.
   PubMed Web of Science ®Google Scholar